Hologic, Inc. (NASDAQ:HOLX) Stake Boosted by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. lifted its position in Hologic, Inc. (NASDAQ:HOLXFree Report) by 4.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,400 shares of the medical equipment provider’s stock after buying an additional 564 shares during the period. Oppenheimer & Co. Inc.’s holdings in Hologic were worth $999,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Hologic by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 27,882,301 shares of the medical equipment provider’s stock valued at $2,141,919,000 after acquiring an additional 381,608 shares during the last quarter. BlackRock Inc. lifted its stake in Hologic by 0.4% during the second quarter. BlackRock Inc. now owns 23,849,548 shares of the medical equipment provider’s stock valued at $1,931,098,000 after purchasing an additional 87,374 shares during the last quarter. State Street Corp boosted its holdings in Hologic by 1.8% during the second quarter. State Street Corp now owns 11,542,769 shares of the medical equipment provider’s stock worth $934,618,000 after buying an additional 206,023 shares in the last quarter. Macquarie Group Ltd. grew its position in Hologic by 227.2% in the second quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock worth $435,485,000 after buying an additional 4,363,687 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Hologic by 1.3% in the second quarter. Geode Capital Management LLC now owns 5,391,310 shares of the medical equipment provider’s stock valued at $435,426,000 after buying an additional 69,276 shares in the last quarter. Institutional investors and hedge funds own 92.64% of the company’s stock.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of recent research reports. William Blair restated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Royal Bank of Canada cut their price objective on Hologic from $74.00 to $72.00 and set a “sector perform” rating on the stock in a report on Friday, November 10th. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, January 18th. UBS Group lifted their target price on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Finally, Raymond James upped their price target on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $86.89.

Get Our Latest Analysis on Hologic

Insiders Place Their Bets

In other news, Director Scott T. Garrett sold 10,000 shares of Hologic stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $68.71, for a total transaction of $687,100.00. Following the completion of the sale, the director now directly owns 47,039 shares in the company, valued at approximately $3,232,049.69. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO Karleen Marie Oberton sold 14,940 shares of Hologic stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the sale, the chief financial officer now owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Scott T. Garrett sold 10,000 shares of the stock in a transaction on Monday, December 11th. The stock was sold at an average price of $68.71, for a total transaction of $687,100.00. Following the transaction, the director now directly owns 47,039 shares in the company, valued at $3,232,049.69. The disclosure for this sale can be found here. Insiders have sold a total of 32,440 shares of company stock valued at $2,346,475 in the last three months. Insiders own 1.75% of the company’s stock.

Hologic Stock Down 0.4 %

Hologic stock opened at $73.85 on Thursday. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $87.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. The firm has a market cap of $17.33 billion, a PE ratio of 35.00, a P/E/G ratio of 2.51 and a beta of 1.02. The firm’s 50 day moving average price is $72.04 and its two-hundred day moving average price is $72.10.

Hologic (NASDAQ:HOLXGet Free Report) last posted its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $989.32 million. During the same period in the previous year, the company posted $1.07 EPS. Hologic’s revenue was down 5.7% on a year-over-year basis. On average, research analysts predict that Hologic, Inc. will post 4.02 EPS for the current fiscal year.

Hologic Company Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Further Reading

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.